MCRB$16.055
Chart
Performance
Key Stats
AI MCRB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralSeres Therapeutics (MCRB) presents a mixed investment profile. While it operates in the promising microbiome therapeutics sector with potential for disruptive innovation, its financial performance has been consistently negative, leading to significant cash burn. The company's stock price has experienced substantial volatility. Investors should closely monitor clinical trial progress and future funding rounds.
Thematic
Seres Therapeutics is focused on the microbiome therapeutics market, a sector with significant growth potential driven by increasing understanding of the gut microbiome's role in health and disease. The company's focus on serious conditions like C. difficile infection and ulcerative colitis targets substantial unmet medical needs.
Fundamental
Seres Therapeutics exhibits significant financial challenges, characterized by a lack of revenue, substantial operating losses, and negative free cash flow. The company relies heavily on financing activities to sustain operations. While cash reserves exist, they are being depleted at a high rate.
Technical
Seres Therapeutics' stock exhibits high volatility and is trading below its 50-day and 200-day moving averages on the daily chart, suggesting a bearish trend. Momentum indicators like RSI are not indicating oversold or overbought conditions, suggesting a period of sideways movement or continued choppiness.
| Factor | Score |
|---|---|
| Microbiome Therapeutics Potential | 80 |
| Targeted Diseases | 75 |
| Competitive Landscape | 65 |
| Regulatory Pathways | 70 |
| Partnership Opportunities | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 20 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 60 |
| Volume Confirmation | 50 |
| Support & Resistance | 55 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Recent Performance Momentum
The stock has shown strong positive performance over the last month (+40.9%) and 5 days (+2.37%), indicating recent upward momentum.
Improving Cash Position
Cash and cash equivalents have increased significantly from $30.79M in Q4 2024 to $67.52M in Q1 2025, suggesting improved liquidity.
Bearish Points (8)
Inconsistent P/E Ratio
The TTM P/E ratio of 1.1 and Q4 2024 P/E of -9.3, contrasted with a positive Q1 2025 P/E of 3.7, indicates significant volatility and difficulty in establishing a stable valuation metric.
Zero Revenue Reported
The company has reported zero revenue for the most recent annual periods (2021-2024) and quarterly periods (2024-2025), raising serious concerns about the underlying business model and revenue generation capabilities.
Calendar
August 2025
6
Next Earnings Date
H: $-1.95
A: $-2.61
L: $-3.27
Profile
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Seasonals
Price Target
13.33 USD
The 39 analysts offering 1 year price forecasts for MCRB have a max estimate of 20.00 and a min estimate of 6.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Provides a leading synthetic biology platform that enables drug discovery and biomanufacturing, crucial for many microbiome-based therapeutic developers.
Weight: 92
Develops molecular diagnostics, including stool-based tests (Cologuard) that analyze DNA biomarkers, inherently linked to gut microbiome components and health.
Weight: 90
Global biopharmaceutical company with a leading presence in immunology, including therapies for Inflammatory Bowel Disease (IBD), a condition directly linked to gut microbiome health and a target area for Seres (MCRB).
Weight: 88
Major biopharmaceutical company with extensive research and development in infectious diseases (e.g., HIV, viral hepatitis), an area with growing recognition of microbiome influence on disease progression and treatment.